Analyst firms · Morgan Stanley · BLCO

Morgan Stanley BLCO price target and rating history

Bausch + Lomb Corporation (BLCO) · Health Care

Morgan Stanley rates Bausch + Lomb Corporation (BLCO) Overweight with a $21 price target, as of its latest action on Dec 2, 2025. It has published 4 rating actions on BLCO since May 2023, including 2 upgrades and 1 downgrade. Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. Morgan Stanley's target matches it.

Current rating
Overweight
Price target
$21
Median target, all firms
$21
Actions on BLCO
4

Morgan Stanley price target on BLCO

$21$20$18202420252026
Morgan Stanley price target on BLCO, each point a stated target, May 2023 to December 2025.

Every Morgan Stanley rating on BLCO

How other firms rate BLCO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightNeutral$22Nov 2, 2026
BarclaysOverweight$24Oct 7, 2026
Leerink PartnersOutperform$24Sep 9, 2026
UBSBuy$21Jul 28, 2026
Evercore ISIIn-line$18Jan 5, 2026
CitigroupBuy$20Dec 11, 2025
Morgan StanleyOverweight$21Dec 2, 2025

Questions about Morgan Stanley and BLCO

What is Morgan Stanley's price target for BLCO?
Morgan Stanley's latest stated price target for Bausch + Lomb Corporation (BLCO) is $21, from its action on Dec 2, 2025.
What is Morgan Stanley's rating on BLCO?
Morgan Stanley rates BLCO Overweight, a bullish rating, as of Dec 2, 2025.
When did Morgan Stanley last change its view on BLCO?
On Dec 2, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $21.
How does Morgan Stanley's BLCO target compare with other analysts?
Across 7 firms with a BLCO price target in the last 12 months, the median target is $21. Morgan Stanley's target matches it.

More BLCO rating histories

All Morgan Stanley ratingsBLCO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.